Posts

Posted on

Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders

STAMFORD, Conn., June 17, 2026 (GLOBE NEWSWIRE) — Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Indaptus Therapeutics, Inc. (Nasdaq: INDP) who held their shares prior to December 22, 2025.

This investigation is to determine whether the Indaptus Board violated its fiduciary duties in connection with a private placement of preferred stock.

Stockholders who have held Indaptus shares since before December 22, 2025, and are interested in learning more about the investigation or their legal rights are encouraged to contact Abbott Cooper PLLC at no cost or obligation.

Abbott Cooper PLLC handles cases on a contingency fee basis, meaning there is no cost to stockholders unless a recovery is obtained.

IF YOU ARE AN INDAPTUS STOCKHOLDER AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, PLEASE CONTACT:

J. Abbott R. Cooper
Abbott Cooper PLLC
1266 East Main Street
Suite 700R
Stamford, CT 06902
(475) 477-5031
[email protected]
https://abbottlawyer.com/

Attorney Advertising. Prior results do not guarantee a similar outcome.



Posted on

Kuehn Law Encourages Investors of Franklin BSP Realty Trust, Inc. to Contact Law Firm

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Franklin BSP Realty Trust, Inc. (NYSE: FBRT) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Franklin BSP Realty Trust misrepresented or failed to disclose that the Company had recklessly overstated: (1) its earnings prospects; and (2) its ability to maintain a $0.355 dividend per share of common stock.

If you currently own FBRT and purchased prior to November 5, 2024 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814



Posted on

Kuehn Law Encourages Investors of Kyndryl Holdings, Inc. to Contact Law Firm

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kyndryl Holdings, Inc. (NYSE: KD) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Kyndryl Holdings misrepresented or failed to disclose that: (1) certain members of executive management engaged in systematic manipulation of the Company’s free cash flow metrics through the deliberate postponement of vendor payments from one fiscal quarter to the next; (2) as a consequence thereof, Kyndryl falsely represented its reported free cash flow metrics as indicative of the quality and long-term sustainability of its earnings and revenue growth, when in reality such cash generation was contingent upon undisclosed and inherently unsustainable cash management practices; (3) the Company’s procedures governing financial disclosures, its accounting methodologies, and its internal controls over financial reporting were materially inadequate and deficient; and (4) by reason of the foregoing, Kyndryl’s business operations, financial condition, and prospects for achieving profitable growth were materially worse than had been publicly represented to investors.

If you currently own KD and purchased prior to August 1, 2024 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814



Posted on

Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) — Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed to disclose adverse facts concerning potential FDA approval of one of the Company’s lead new product candidates, relacorilant, a medication being developed for multiple indications, including the treatment of hypercortisolism, or Cushing’s syndrome. While the Company touted the expected success of FDA approval, it failed to disclose that the FDA had in fact expressed concerns to Corcept about the adequacy of the Company’s clinical development program assessing relacorilant’s effectiveness and that relacorilant’s New Drug Application faced a material risk of rejection.

If you currently own CORT and purchased prior to October 31, 2024 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients.Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™  

For additional information, please visit Shareholder Derivative Litigation – Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814



Posted on

Broadcom Inc. Announces Results and Upsize of Offers to Purchase for Cash Certain of its Outstanding Debt Securities

PR Newswire

PALO ALTO, Calif., June 17, 2026 /PRNewswire/ — Broadcom Inc. (NASDAQ: AVGO) (“Broadcom“) today announced the expiration and results of its previously announced cash tender offers (collectively, the “Offers“) to purchase any and all of its outstanding 4.926% Senior Notes due 2037; 4.900% Senior Notes due 2038; 5.050% Senior Notes due 2030; 5.200% Senior Notes due 2032; 5.150% Senior Notes due 2031 and 4.900% Senior Notes due 2032 (collectively, the “Notes“). 

Broadcom also announced that it is increasing the aggregate purchase price, excluding the Accrued Coupon Payment, from the previously announced amount of $2.5 billion to $3.0 billion (the “Consideration Cap Amount“). The increased Consideration Cap Amount is sufficient to enable Broadcom to purchase all of the 4.926% Senior Notes due 2037 and 4.900% Senior Notes due 2038, in each case, that were validly tendered prior to or at the Expiration Date, as well as all of the Notes of such Series that were tendered pursuant to the Guaranteed Delivery Procedures.

The Offers were made upon the terms and subject to the conditions set forth in the Offer to Purchase dated June 11, 2026 (the “OffertoPurchase“) and the accompanying notice of guaranteed delivery (the “Noticeof Guaranteed Delivery“). Capitalized terms used but not defined in this press release have the meanings given to them in the Offer to Purchase.

The Offers expired at 5:00 p.m., New York City time, on June 17, 2026 (the “ExpirationDate“). As the Withdrawal Deadline has passed, tendered Notes may no longer be validly withdrawn, except as required by applicable law. The Initial Settlement Date will be June 18, 2026. For the Holders using the Guaranteed Delivery Procedures, the Guaranteed Delivery Date will be 5:00 p.m., New York City time, on June 22, 2026. The Guaranteed Delivery Settlement Date will be June 23, 2026.

According to information provided by D.F. King & Co., Inc., the Tender and Information Agent in connection with the Offers, approximately $5.5 billion combined aggregate principal amount of Notes were validly tendered prior to or at the Expiration Date, of which approximately $2.9 billion aggregate principal amount of Notes have been accepted for purchase. In addition, as of the Expiration Date, approximately $35.0 million combined aggregate principal amount of 4.926% Senior Notes due 2037 and 4.900% Senior Notes due 2038 were tendered pursuant to the Guaranteed Delivery Procedures but remain subject to the Holders’ performance of the delivery requirements under such procedures. The table below provides certain information about the Offers as of the Expiration Date.


Series of
Notes


CUSIP/ISIN
Number

(1)


Aggregate
Principal
Amount
Outstanding


Acceptance
Priority
Level


Total
Consideration

(2)


Principal
Amount
Tendered

(3)


Principal Amount
Accepted

(3)


Principal
Amount
Reflected in
Notices of
Guaranteed
Delivery

4.926% Senior
Notes due
2037

144A: 11135FBV2 /
US11135FBV22
RegS:
U1109MBA3 /
USU1109MBA37

$2,500,000,000

1

$982.01

$1,843,836,000

$1,843,836,000

$17,241,000

4.900% Senior
Notes due
2038

11135FCX7 /
US11135FCX78

$1,750,000,000

2

$970.29

$1,050,537,000

$1,050,537,000

$17,749,000

5.050% Senior
Notes due
2030

11135FCF6 /
US11135FCF62

$800,000,000

3

$1,021.24

$571,143,000

—

$9,356,000

5.200% Senior
Notes due
2032

11135FCG4 /
US11135FCG46

$1,100,000,000

4

$1,023.23

$636,171,000

—

$17,620,000

5.150% Senior
Notes due
2031

11135FBY6 /
US11135FBY60

$1,500,000,000

5

$1,021.77

$761,332,000

—

$54,393,000

4.900% Senior
Notes due
2032

11135FCL3 /
US11135FCL31

$1,750,000,000

6

$1,003.73

$628,421,000

—

$10,998,000

______________________

(1)   No representation is made as to the correctness or accuracy of the CUSIP or ISIN numbers listed above.

(2)   Represents the total consideration for each Series of Notes (the “Total Consideration“) payable per each $1,000 principal amount of such Series of Notes validly tendered for purchase.

(3)   The amounts exclude the principal amounts of tendered Notes that remain subject to the Holder’s performance of the delivery requirements under the Guaranteed Delivery Procedures. 

Broadcom’s obligation to complete an Offer with respect to the Notes validly tendered is conditioned on the satisfaction or waiver of conditions described in the Offer to Purchase. For the Notes accepted for purchase, all conditions to the Offer with respect to such Notes were satisfied or waived on or prior to the Expiration Date. On the applicable Settlement Date, Holders whose Notes have been accepted for purchase will also receive an Accrued Coupon Payment. The Notes validly tendered but not accepted for purchase will be returned promptly to the tendering Holders in accordance with the Offer to Purchase.

Broadcom has retained Barclays Capital Inc. and Citigroup Global Markets Inc. to act as dealer managers (the “Dealer Managers“) for the Offers. D.F. King & Co., Inc. is acting as the Tender and Information Agent for the Offers. For additional information, please contact: Barclays Capital Inc. at +1 (800) 438-3242 (toll-free) or +1 (212) 528-7581 (collect); or Citigroup Global Markets Inc. at +1 (800) 558-3745 (toll-free) or +1 (212) 723-6106 (collect). Requests for documents and questions regarding the tendering of Notes may be directed to D.F. King & Co., Inc. by telephone at +1 (212) 257-2468 (for banks and brokers only) and +1 (800) 967-7635 (for all others toll-free), by email at [email protected] or to the Dealer Managers at their respective telephone numbers. Copies of the Offer to Purchase and the Notice of Guaranteed Delivery are available at: www.dfking.com/avgo. You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Offers.

This press release is neither an offer to purchase nor a solicitation of an offer to sell the Notes or any other securities. The Offers were made only by and pursuant to the terms of the Offer to Purchase and only to such persons and in such jurisdictions as is permitted under applicable law. The information in this press release is qualified by reference to the Offer to Purchase.

Forward-Looking Statements

This press release contains forward-looking statements (within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended). These forward-looking statements are based on current expectations and beliefs of Broadcom’s management, current information available to Broadcom’s management, and current market trends and market conditions, and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Accordingly, undue reliance should not be placed on such statements. All forward-looking statements are qualified in their entirety by reference to the risk factors discussed under the heading “Risk Factors” in Broadcom’s Annual Report on Form 10-K for the year ended November 2, 2025, Quarterly Reports on Form 10-Q for the periods ended February 1, 2026 and May 3, 2026, and any subsequent reports that are filed with the Securities and Exchange Commission and include some important risk factors that may affect future results. Broadcom undertakes no intent or obligation to publicly update or revise the forward-looking statements made in this press release, except as required by law.

About Broadcom

Broadcom Inc. (NASDAQ: AVGO) is a technology leader that designs, develops, and supplies semiconductors and infrastructure software for global organizations’ complex, mission-critical needs. Broadcom combines long-term R&D investment with superb execution to deliver the best technology, at scale. Broadcom is a Delaware corporation headquartered in Palo Alto, CA.

Contact

Ji Yoo
Investor Relations
[email protected]
650-427-6000

(AVGO-Q)

Cision View original content:https://www.prnewswire.com/news-releases/broadcom-inc-announces-results-and-upsize-of-offers-to-purchase-for-cash-certain-of-its-outstanding-debt-securities-302803781.html

SOURCE Broadcom Inc.

Posted on

NETLIST EXPANDS LEGAL ACTION AGAINST SAMSUNG AND GOOGLE FOR INFRINGEMENT OF NEW AI MEMORY PATENTS

PR Newswire

– Files actions with the ITC and the EDTX –

IRVINE, Calif., June 17, 2026 /PRNewswire/ — Netlist, Inc. (OTCBQ: NLST) today announced it has initiated new legal proceedings against Samsung in the U.S. International Trade Commission (ITC) and the U.S. District Court for the Eastern District of Texas.  These actions are based on the infringement of Netlist’s U.S. Patent Nos. 12,646,537 and 12,650,937, which respectively read on Samsung’s high-bandwidth memory (HBM) products and Samsung’s DDR5 RDIMMs and MRDIMMs. The new ITC complaint names Google, Supermicro, Nvidia and Broadcom as additional respondents.

Netlist, Inc.

C.K. Hong, Netlist’s Chief Executive Officer, said, “Netlist continues to drive breakthrough innovations in AI memory. These enforcement actions expand our efforts to protect next-generation server DIMM and HBM technologies against unauthorized use.”

At the ITC, Netlist is seeking exclusion and cease and desist orders against Samsung and other respondents. The ITC investigates and makes determinations against unfair acts in the import trade that violate U.S. intellectual property rights. ITC investigations proceed on an expedited basis, commonly progressing to trial within a year.

Netlist is represented by Sterne Kessler Goldstein & Fox and Irell & Manella.

About Netlist

Netlist is a leading innovator in advanced memory and storage solutions. With a rich portfolio of patented technologies, Netlist’s inventions are foundational to the advancement of AI computing. To learn more about Netlist, please visit www.netlist.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release include, without limitation, statements about Netlist’s positioning to capitalize on next generation memory products, and evaluations and judgements regarding Netlist’s products and intellectual property portfolio. Forward-looking statements are statements other than historical facts and often address future events or Netlist’s future performance. They reflect management’s present expectations regarding future events and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in or implied by any forward-looking statements. These risks, uncertainties and other factors include, among others, risks: Netlist may not be able to collect the substantial amount in damages previously awarded to it in its litigations (appeals in general could cause a lengthy delay in Netlist’s ability to collect damages awards, could overturn the verdicts or reduce the damages awards); Netlist will suffer adverse outcomes in its litigation with Samsung, Micron or Google or in its various other active proceedings to defend the validity of its patents; related to Netlist’s plans for its intellectual property, including its strategies for monetizing, licensing, expanding, and defending its patent portfolio, which efforts may not be successful; that other patent infringement litigation initiated by Netlist, or by others against Netlist, may not be successful or resolve favorably for Netlist, particularly given the costs and unpredictability of any such litigation; associated with Netlist’s product sales, including whether and how long the current market and demand for products sold by Netlist will persist or persist as expected and whether Netlist may successfully develop and launch new products that are attractive to the market; whether Netlist will continue to acquire components or products for resale on favorable terms; associated with the competitive landscape of Netlist’s industry, general economic, political and market conditions, factory slowdowns and/or shutdowns, and changes in international trade and tariff policies. All forward-looking statements reflect management’s present assumptions, expectations and beliefs regarding future events and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in or implied by any forward-looking statements. These and other risks and uncertainties are described in Netlist’s Annual Report on Form 10-K for the fiscal year ended December 27, 2025 filed with the SEC on March 19, 2026, and the other filings it makes with the U.S. Securities and Exchange Commission from time to time, including any subsequently filed quarterly and current reports. In light of these risks, uncertainties and other factors, these forward-looking statements should not be relied on as predictions of future events. These forward-looking statements represent Netlist’s assumptions, expectations and beliefs only as of the date they are made, and except as required by law, Netlist undertakes no obligation to revise or update any forward-looking statements for any reason.

For more information, please contact:

Investors / Media
Mike Smargiassi
The Plunkett Group
[email protected]
(212) 739‑6729

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/netlist-expands-legal-action-against-samsung-and-google-for-infringement-of-new-ai-memory-patents-302803791.html

SOURCE Netlist, Inc.

Posted on

Legend Biotech Corporation Announces Pricing of Public Offering

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, are expected to be approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. The offering is expected to close on June 23, 2026, subject to customary closing conditions.

Morgan Stanley, Jefferies, Citigroup and Deutsche Bank Securities are serving as joint book-running managers for the offering.

The ADSs are being offered by Legend Biotech pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (“SEC”). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on June 17, 2026. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. A copy of the final prospectus supplement and the accompanying prospectus can be obtained, when available, from Morgan Stanley Asia Limited, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, email: [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone: (877) 821-7388, or by email: [email protected]; Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone: (800) 831-9146; or Deutsche Bank Securities Inc., Attention: Prospectus Group, 1 Columbus Circle, New York, NY 10019, by telephone: (800) 503-4611, or by email: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Legend Biotech

With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the closing of and expected gross proceeds from the public offering. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors
, including: the uncertainties related to market conditions and the completion of the proposed public offering on the anticipated terms or at all
, and the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 10, 2026 as well as in Legend Biotech’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated or expected. Any forward-looking statements contained in this press release speak only as of the date hereof, and Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Readers should not rely upon the information in this press release as current or accurate after its publication date.

INVESTOR CONTACT:

Jessie Yeung
Tel: (732) 956-8271
[email protected]

PRESS CONTACT:

Kim Fox
Tel: (848) 388-8445
[email protected]



Posted on

Yorkville International Capital Corp. Announces Closing of $230,000,000 Initial Public Offering

MOUNTAINSIDE, N.J., June 17, 2026 (GLOBE NEWSWIRE) — Yorkville International Capital Corp. (the “Company”) announced today that it closed its initial public offering of 23,000,000 units, including the issuance of 3,000,000 units as result of the underwriters’ exercise of their over-allotment option in full, at $10.00 per unit. The gross proceeds from the offering were $230 million before deducting underwriting discounts and estimated offering expenses. The units began trading on the Global Market tier of The Nasdaq Stock Market (“Nasdaq”) under the ticker symbol “YICCU” on June 16, 2026.

Each unit consists of one Class A ordinary share and one-third of one redeemable warrant. Each whole warrant entitles the holder to purchase one Class A ordinary share of the Company at a price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “YICC” and “YICCW,” respectively.

Cohen & Company Capital Markets, a division of Cohen & Company Securities, LLC (“CCM”), acted as the sole book-running manager in the offering.

A registration statement on Form S-1 (333-295912) relating to these securities sold in the initial public offering has been filed with the Securities and Exchange Commission (“SEC”) and was declared effective on June 15, 2026. The offering was made by means of a prospectus. Copies of the prospectus may be obtained from CCM, Attn: Cohen & Company Capital Markets, 3 Columbus Circle, 24th floor, New York, NY 10019, by email at [email protected], or from the SEC website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Yorkville International Capital Corp.

The Company is a blank check company incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The Company has not selected any specific business combination target and has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination. While the Company may pursue a business combination target in any business, sector or geographic location, it intends to focus its search on established businesses operating in emerging markets, with a particular emphasis on Latin America and Venezuela.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the registration statement and related final prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, www.sec.gov.

Contact Information:

Yorkville International Capital Corp.
1012 Springfield Avenue
Mountainside, New Jersey 07092

Kevin McGurn
Chief Executive Officer
Phone : (201) 985-8300
Email : [email protected]



Posted on

Kardigan Announces Pricing of Upsized Initial Public Offering

Kardigan Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.–(BUSINESS WIRE)–
Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan”), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price of $16 per share. The gross proceeds from the offering are expected to be $400 million, before underwriting discounts and commissions and estimated offering expenses payable by Kardigan, and excluding any exercise of the underwriters’ option to purchase additional shares. In addition, Kardigan has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares at the initial public offering price, less underwriting discounts and commissions. All shares are being offered by Kardigan.

Kardigan’s common stock is expected to begin trading on the Nasdaq Global Market on June 18, 2026, under the ticker symbol “KARD.” The offering is expected to close on June 22, 2026, subject to customary closing conditions.

J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC, and TD Securities (USA) LLC are the underwriters for the offering.

Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission and became effective on June 17, 2026. This offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at [email protected] and [email protected]; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at [email protected]; Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at [email protected]; and TD Securities (USA) LLC, by mail at TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected].

This news release does not constitute an offer to sell, or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Kardigan

Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Led by a proven and experienced management team, Kardigan is reimagining cardiovascular drug discovery and development through an integrated approach that unites deep cardiovascular biology, real-world patient data, and advanced analytics to enable more precise, efficient, and informed development of novel therapies. The company is based in South San Francisco, California and Princeton, New Jersey.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding Kardigan’s expectations regarding the commencement of trading of its shares on the Nasdaq Global Market, the completion and timing of the closing of the offering and the anticipated gross proceeds from the offering. Forward-looking statements are based on Kardigan’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to market conditions, the satisfaction of customary closing conditions and the completion of the offering, and the risks inherent in pharmaceutical product development and clinical trials. These and other risks and uncertainties are described more fully in the “Risk Factors” section of the registration statement filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Kardigan undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information in this press release as current or accurate after its publication date.

Media:

Michael Bachner

Executive Director, Corporate Communications

+1 (609) 664-7308

[email protected]

Investors:

Clayton Robertson

Vice President, Investor Relations

[email protected]

KEYWORDS: United States North America California New Jersey

INDUSTRY KEYWORDS: Cardiology Biotechnology FDA Other Health Health General Health Pharmaceutical Other Science Research Science Clinical Trials

MEDIA:

Logo
Logo
Posted on

First Carolina Financial Services Announces Pricing of Initial Public Offering

First Carolina Financial Services Announces Pricing of Initial Public Offering

RALEIGH, N.C.–(BUSINESS WIRE)–First Carolina Financial Services, Inc. (“First Carolina” or the “Company”), the holding company for First Carolina Bank (“Bank”), announced today the pricing of its initial public offering of 5,500,000 shares of its common stock at an initial public offering price of $12.50 per share. The shares are expected to begin trading on June 18, 2026 on the New York Stock Exchange under the ticker symbol “FCBM.” The closing of the offering is expected to occur on June 22, 2026, subject to the satisfaction of customary closing conditions. In addition, First Carolina has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

First Carolina intends to use the net proceeds from the offering for general corporate purposes, which may include supporting organic growth, potential acquisitions, refinancing of outstanding indebtedness, and working capital.

Keefe, Bruyette & Woods, A Stifel Company, is acting as sole bookrunner in the offering. Raymond James and Hovde Group are acting as co-managers.

A registration statement on Form S-1 (including a preliminary prospectus) relating to these securities was declared effective by the Securities and Exchange Commission on June 17, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering, when available, may be obtained by contacting Keefe, Bruyette & Woods, Inc., Attn: Equity Capital Markets, by Telephone: (800) 966-1559 or Email: [email protected].

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Investors may also view the registration statement, preliminary prospectus and, when available, the final prospectus on the SEC’s website at www.sec.gov.

About First Carolina Financial Services, Inc.

First Carolina Financial Services, Inc. operates as a bank holding company for First Carolina Bank that provides financial services for businesses, higher education institutions, and individuals. First Carolina offers a range of deposit and loan products and trust services. First Carolina is headquartered in Raleigh, North Carolina with full-service banking offices in Rocky Mount, Raleigh, Wilmington, Cary, and Reidsville, North Carolina; Virginia Beach, Virginia; Columbia and Greenville, South Carolina; and Atlanta, Georgia.

Company Note Regarding Forward-Looking Statements

This press release contains, and future oral and written statements by us and our management may contain, forward-looking statements. These forward-looking statements represent plans, estimates, objectives, goals, guidelines, expectations, intentions, projections, and statements of the Company’s beliefs concerning future events, business plans, objectives, expected operating results and the assumptions upon which those statements are based. Forward-looking statements include, without limitation, statements concerning the satisfaction of customary closing conditions and the completion of the offering, the anticipated use of proceeds from the offering, the expected listing on the New York Stock Exchange and any other statement that may predict, forecast, indicate or imply future results, performance or achievements, and are typically identified with words such as “may,” “could,” “should,” “will,” “would,” “believe,” “anticipate,” “estimate,” “expect,” “aim,” “intend,” “plan” or words or phases of similar meaning. We caution that the forward-looking statements are based largely on our expectations and are subject to a number of known and unknown risks and uncertainties that are subject to change based on factors which are, in many instances, beyond our control and could cause actual results to differ materially from those currently anticipated. Such risks and uncertainties include, but are not limited to: adverse developments in our borrowers’ industries and, in particular, declines in real estate values; our ability to maintain compliance with federal and state laws that regulate our business and capital levels; our ability to raise capital as needed by our business; our ability to manage growth; the loss of any of our key employees; changes in the interest rates affecting our deposits, loans, and securities portfolio; our ability to maintain adequate liquidity and control our cost of funds; the strength of the economy in our current and future market areas, as well as general economic, market, or business conditions; negative developments in the financial industry and credit markets; an insufficient allowance for credit losses as a result of inaccurate assumptions or otherwise; the ability of our current and any future markets to weather a downturn in the economy; our potential growth, including our entrance or expansion into new markets, the opportunities that may be presented to and pursued by us and the need for sufficient capital to support that growth; changes in our competitive position, competitive actions by other financial institutions and the competitive nature of the financial services industry and our ability to compete effectively against other financial institutions in our banking markets; changes in laws, regulations and the policies of federal or state regulators and agencies; governmental monetary and fiscal policies, including the policies of the Federal Reserve; our ability to maintain internal control over financial reporting and an effective risk management framework; our effective use of technology or an interruption or breach in security of our information systems; our reliance on secondary sources, such as FHLB advances, sales of securities and loans, federal funds lines of credit from correspondent banks and out-of-market time deposits, to meet our liquidity needs; inaccurate or incomplete information about our clients; our ability to assess and manage our asset quality; natural disasters, pandemics or other public health crises, war, terrorist activities or civil unrest and their effects on the economic and business environments in which we operate; and risks associated with unauthorized access, cyber-crime and other threats to data security. We assume no obligation and do not intend to update these forward-looking statements, except as required by law.

Kristen Brabble
Chief Operating Officer
252-451-2964

Diane Fitzgibbons
The IR Group
206-388-5789

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Personal Finance Finance Banking Professional Services Small Business

MEDIA:

Logo
Logo